Aspen continues spending spree with $372m purchase

accreditation
Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!
(iStock)
(iStock)

Johannesburg - Aspen Pharmacare [JSE:APN] has agreed to buy a portfolio of anaesthetic medicines from GlaxoSmithKline for as much as $372m as Africa’s biggest maker of generic drugs continues a spending spree.

The company will pay an initial $239m to Glaxo and disburse as much as $133m if certain goals are met, the South Africa-based drugmaker said in a statement on Monday.

The deal adds to the anaesthetics Aspen bought in June from AstraZeneca of the UK for as much as $770m. 

Support independent journalism
Subscribe to News24 for just R75 per month to read all our investigative and in-depth journalism.
Subscribe
Already a subscriber? Sign in
Rand - Dollar
14.24
+0.4%
Rand - Pound
19.83
-0.4%
Rand - Euro
16.97
-0.1%
Rand - Aus dollar
10.73
-0.3%
Rand - Yen
0.13
+0.3%
Gold
1,783.14
+1.1%
Silver
25.98
+0.7%
Palladium
2,568.21
+4.1%
Platinum
1,054.00
+1.5%
Brent Crude
73.51
+0.6%
Resource 10
61,142
+0.3%
Industrial 25
87,978
+0.0%
Financial 15
12,871
-1.0%
Top 40
59,472
-0.1%
All Share
65,564
-0.1%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot
Voting Booth
Should government have assigned a majority shareholding in SAA to the private sector?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes, It's a good decision
66% - 233 votes
Not a good move
9% - 33 votes
Too early to tell
25% - 88 votes
Vote